{
  "source": "PA-Notification-Adalimumab.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1041-19\nProgram Prior Authorization/Notification\nMedication Adalimumab: Abrilada™ (adalimumab-afzb)*, Adalimumab-aacf\n(unbranded Idacio)*, Adalimumab-adaz (unbranded Hyrimoz),\nAdalimumab-adbm (unbranded Cyltezo)*, Adalimumab-fkjp\n(unbranded Hulio)*, Amjevita™ (adalimumab-atto), Cyltezo®\n(adalimumab-adbm)*, Hadlima™ (adalimumab-bwwd)*, Hulio®\n(adalimumab-fkjp)*, Humira® (adalimumab), Hyrimoz® (adalimumab-\nadaz)*, Idacio® (adalimumab-aacf)*, Simlandi® (adalimumab-ryvk)*,\nYuflyma® (adalimumab-aaty)*, and Yusimry™ (adalimumab-aqvh)*\n* Abrilada (adalimumab-afzb), Adalimumab-aacf (unbranded Idacio),\nAdalimumab-adbm (unbranded Cyltezo), Adalimumab-fkjp (unbranded\nHulio), Cyltezo (adalimumab-adbm), Hadlima (adalimumab-bwwd),\nHulio (adalimumab-fkjp), Hyrimoz (adalimumab-adaz), Idacio\n(adalimumab-aacf), Simlandi (adalimumab-ryvk), Yuflyma\n(adalimumab-aaty), Yusimry (adalimumab-aqvh) are excluded from\ncoverage for the majority of our benefits.\nP&T Approval Date 1/2007, 6/2008, 4/2009, 6/2009, 12/2009, 7/2010, 11/2010, 7/2011,\n11/2011, 7/2012, 11/2012, 2/2014, 2/2015, 11/2015, 3/2016, 8/2016,\n8/2017, 8/2018, 8/2019, 4/2020, 5/2021, 12/2021, 12/2022, 4/2023,\n6/2023, 6/2024, 10/2024, 4/2025\nEffective Date 6/1/2025\n1. Background:\nAdalimumab is a tumor necrosis factor (TNF) blocker indicated for:\n• Rheumatoid Arthritis (RA): reducing signs and symptoms, inducing major clinical response,\ninhibiting the progression of structural damage, and improving physical function in adult patients\nwith moderately to severely active RA. Adalimumab can be used alone or in combination with\nmethotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs).\n• Juvenile Idiopathic Arthritis (JIA): reducing signs and symptoms of moderately to severely active\npolyarticular JIA in patients 2 years of age and older. Adalimumab can be used alone or in\ncombination with methotrexate.\n• Psoriatic Arthritis (PsA): reduci",
    " symptoms of moderately to severely active\npolyarticular JIA in patients 2 years of age and older. Adalimumab can be used alone or in\ncombination with methotrexate.\n• Psoriatic Arthritis (PsA): reducing signs and symptoms, inhibiting the progression of structural\ndamage, and improving physical function in adult patients with active PsA.\n• Ankylosing Spondylitis (AS): reducing signs and symptoms in adult patients with active AS.\nAdalimumab can be used alone or in combination with non-biologic DMARDs.\n• Crohn’s Disease (CD): treatment of moderately to severely active Crohn’s disease in adults and\npediatric patients 6 years of age and older.\n• Ulcerative Colitis (UC): treatment of moderately to severely active ulcerative colitis in adults and\npediatric patients 5 years of age and older.\n• Plaque Psoriasis (Ps): treatment of adult patients with moderate to severe chronic plaque psoriasis\nwho are candidates for systemic therapy or phototherapy, and when other systemic therapies are\nmedically less appropriate.\n• Hidradenitis Suppurativa (HS): treatment of moderate to severe hidradenitis suppurativa in\npatients 12 years of age and older.\n© 2025 UnitedHealthcare Services, Inc.\n1\n• Uveitis (UV): treatment of non-infectious intermediate, posterior, and panuveitis in adults and\npediatric patients 2 years of age and older.\nIn ulcerative colitis, effectiveness has not been established in patients who have lost response to or\nwere intolerant to TNF blockers.\n2. Coverage Criteriaa:\nA. Rheumatoid Arthritis (RA)\n1. Initial Authorization\na. Adalimumab will be approved based on both of the following criteria:\n(1) Diagnosis of moderately to severely active rheumatoid arthritis\n-AND-\n(2) Patient is not receiving adalimumab in combination with another targeted\nimmunomodulator. [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant (baricitinib),\nRinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\n2. Reau",
    "(etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant (baricitinib),\nRinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Adalimumab will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to adalimumab therapy\n-AND-\n(2) Patient is not receiving adalimumab in combination with another targeted\nimmunomodulator. [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant (baricitinib),\nRinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\nB. Polyarticular Juvenile Idiopathic Arthritis (PJIA)\n1. Initial Authorization\na. Adalimumab will be approved based on both of the following criteria:\n(1) Diagnosis of moderately to severely active polyarticular juvenile idiopathic\narthritis\n-AND-\n© 2025 UnitedHealthcare Services, Inc.\n2\n(2) Patient is not receiving adalimumab in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant (baricitinib),\nRinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Adalimumab will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to adalimumab therapy\n-AND-\n(2) Patient is not receiving adalimumab in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant (baricitinib),\nRinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\nC. Psoriatic Arthritis (PsA)\n1. Initial Authorization\na. Adalimumab will be approved based on both of the following criteria:\n(1) Diagnosis of active psoriatic arthritis\n-AND-\n(2) Patient is not receiving adalimumab in combination with another targeted\nimmunomodulator [e.g., Enbrel ",
    "d based on both of the following criteria:\n(1) Diagnosis of active psoriatic arthritis\n-AND-\n(2) Patient is not receiving adalimumab in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Orencia (abatacept), ustekinumab, Skyrizi (risankizumab),\nTremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Xeljanz\n(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Adalimumab will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to adalimumab therapy\n-AND-\n(2) Patient is not receiving adalimumab in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n© 2025 UnitedHealthcare Services, Inc.\n3\n(golimumab), Orencia (abatacept), ustekinumab, Skyrizi (risankizumab),\nTremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Xeljanz\n(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]\nAuthorization will be issued for 12 months.\nD. Plaque Psoriasis\n1. Initial Authorization\na. Adalimumab will be approved based on both of the following criteria:\n(1) Diagnosis of moderate to severe chronic plaque psoriasis\n-AND-\n(2) Patient is not receiving adalimumab in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Orencia (abatacept), ustekinumab, Skyrizi (risankizumab),\nTremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Siliq\n(brodalumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant\n(baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Adalimumab will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to adalimumab therapy\n-AND-\n(2) Patient is not receiving ada",
    "\n2. Reauthorization\na. Adalimumab will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to adalimumab therapy\n-AND-\n(2) Patient is not receiving adalimumab in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Orencia (abatacept), ustekinumab, Skyrizi (risankizumab),\nTremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Siliq\n(brodalumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant\n(baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]\nAuthorization will be issued for 12 months.\nE. Ankylosing Spondylitis (AS)\n1. Initial Authorization\na. Adalimumab will be approved based on both of the following criteria:\n(1) Diagnosis of active ankylosing spondylitis\n© 2025 UnitedHealthcare Services, Inc.\n4\n-AND-\n(2) Patient is not receiving adalimumab in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant (baricitinib),\nRinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Adalimumab will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to adalimumab therapy\n-AND-\n(2) Patient is not receiving adalimumab in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant (baricitinib),\nRinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\nF. Crohn’s Disease (CD)\n1. Initial Authorization\na. Adalimumab will be approved based on both of the following criteria:\n(1) Diagnosis of moderately to severely active Crohn’s disease\n-AND-\n(2) Patient is not receiving adalimumab in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Entyvio (vedolizumab",
    " disease\n-AND-\n(2) Patient is not receiving adalimumab in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Entyvio (vedolizumab), Omvoh (mirikizumab-mrkz), Tremfya\n(guselkumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant (baricitinib),\nRinvoq (upadacitinib), ustekinumab, Skyrizi (risankizumab)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Adalimumab will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to adalimumab therapy\n-AND-\n© 2025 UnitedHealthcare Services, Inc.\n5\n(2) Patient is not receiving adalimumab in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Entyvio (vedolizumab), Omvoh (mirikizumab-mrkz), Tremfya\n(guselkumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant (baricitinib),\nRinvoq (upadacitinib), ustekinumab, Skyrizi (risankizumab)]\nAuthorization will be issued for 12 months.\nG. Ulcerative Colitis\n1. Initial Authorization\na. Adalimumab will be approved based on all of the following criteria:\n(1) Diagnosis of moderately to severely active ulcerative colitis\n-AND-\n(2) Patient is not receiving adalimumab in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Entyvio (vedolizumab), Omvoh (mirikizumab-mrkz), Tremfya\n(guselkumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant (baricitinib),\nRinvoq (upadacitinib), ustekinumab, Skyrizi (risankizumab)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Adalimumab will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to adalimumab therapy\n-AND-\n(2) Patient is not receiving adalimumab in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Orencia (abatacept), Xeljanz (t",
    "ND-\n(2) Patient is not receiving adalimumab in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Entyvio (vedolizumab),\nOmvoh (mirikizumab-mrkz), Tremfya (guselkumab), Olumiant (baricitinib),\nRinvoq (upadacitinib), ustekinumab, Skyrizi (risankizumab)]\nAuthorization will be issued for 12 months.\nH. Hidradenitis Suppurativa (HS)\n1. Initial Authorization\na. Adalimumab will be approved based on both of the following criteria:\n(1) Diagnosis of moderate to severe hidradenitis suppurativa\n© 2025 UnitedHealthcare Services, Inc.\n6\n-AND-\n(2) Patient is not receiving adalimumab in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant (baricitinib),\nRinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Adalimumab will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to adalimumab therapy.\n-AND-\n(2) Patient is not receiving adalimumab in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant (baricitinib),\nRinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\nI. Uveitis (UV)\n1. Initial Authorization\na. Adalimumab will be approved based on both of the following criteria:\n(1) Diagnosis of non-infectious uveitis\n-AND-\n(2) Patient is not receiving adalimumab in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant (baricitinib),\nRinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Adalimumab will be approved based on both of the following criteria:\n(1) Documentation of positive cl",
    "citinib),\nRinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Adalimumab will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to adalimumab therapy.\n-AND-\n(2) Patient is not receiving adalimumab in combination with another targeted\n© 2025 UnitedHealthcare Services, Inc.\n7\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant (baricitinib),\nRinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n* Abrilada (adalimumab-afzb), Adalimumab-aacf (unbranded Idacio), Adalimumab-adbm (unbranded\nCyltezo), Adalimumab-fkjp (unbranded Hulio), Cyltezo (adalimumab-adbm), Hadlima (adalimumab-\nbwwd), Hulio (adalimumab-fkjp), Hyrimoz (adalimumab-adaz), Idacio (adalimumab-aacf), Simlandi\n(adalimumab-ryvk), Yuflyma (adalimumab-aaty), Yusimry (adalimumab-aqvh) are excluded from\ncoverage for the majority of our benefits.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits and Medical Necessity may be in place.\n4. References:\n1. Humira [package insert]. North Chicago, IL: AbbVie Inc.; February 2024.\n2. Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline:\nUlcerative Colitis in Adults. Am J Gastroenterol. 2019;114(3):384-413.\n3. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association\nInstitute medical position statement on corticosteroids, immunomodulators, and inf",
    "rol. 2019;114(3):384-413.\n3. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association\nInstitute medical position statement on corticosteroids, immunomodulators, and infliximab in\ninflammatory bowel disease. Gastroenterology 2006 Mar;130(3):935-9.\n4. Amjevita [package insert]. Thousand Oaks, CA: Amgen Inc.; August 2023.\n5. Cyltezo [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; June 2023\n6. Hyrimoz [package insert]. Princeton, NJ: Sandoz, Inc.; April 2023.\n7. Hadlima [package insert]. Jersey City, NJ: Organon & Co.; July 2023.\n8. Hulio [package insert]. Morgantown, WV: Mylan Pharmaceuticals Inc.; December 2023.\n9. Yusimry [package insert]. Redwood City, CA: Coherus BioSciences, Inc.; September 2023.\n10. Yuflyma [package insert]. Jersey City, NJ: Celltrion USA, Inc.; December 2023.\n11. Idacio [package insert], Lake Zurich, IL: Fresenius Kabi USA, LLC; October 2023.\n12. Abrilada [package insert], New York, NY: Pfizer, Inc.; January 2024.\n13. Simlandi [package insert], Leesburg, VA: Alvotech USA Inc.; February 2024.\nProgram Prior Authorization/Notification – Adalimumab: Abrilada\n(adalimumab-afzb)*, Adalimumab-aacf (unbranded Idacio)*,\nAdalimumab-adaz (unbranded Hyrimoz), Adalimumab-adbm\n(unbranded Cyltezo)*, Adalimumab-fkjp (unbranded Hulio)*, Amjevita\n(adalimumab-atto), Cyltezo (adalimumab-adbm)*, Hadlima\n(adalimumab-bwwd)*, Hulio (adalimumab-fkjp)*, Humira\n© 2025 UnitedHealthcare Services, Inc.\n8\n(adalimumab), Hyrimoz (adalimumab-adaz)*, Idacio (adalimumab-\naacf)*, Simlandi (adalimumab-ryvk)*, Yuflyma (adalimumab-aaty)*,\nand Yusimry (adalimumab-aqvh)*\nChange Control\n2/2014 Background updated. Concomitant therapy criterion condensed to list\nfour biologic DMARDs and revised to include Xeljanz. Reauthorization\ncriteria revised to standard verbiage and to include concomitant therapy\ncriterion. Extended reauthorization duration to 24 months.\n9/2014 Administrative change – Tried/Failed exemption for State of New\n",
    "teria revised to standard verbiage and to include concomitant therapy\ncriterion. Extended reauthorization duration to 24 months.\n9/2014 Administrative change – Tried/Failed exemption for State of New\nJersey removed.\n2/2015 Annual review with no change to coverage criteria. Minor reformatting.\nUpdated background and references.\n11/2015 Added the indication and criteria for hidradenitis suppurativa. Updated\ncriteria to align with the Indication Section of the FDA label. Updated\nbackground and references.\n3/2016 Annual review. Added criteria back with language that Humira cannot\nbe used in combination with biologic DMARDs, a Janus Kinase\nInhibitor, or a Phosphodiesterase 4 inhibitor for the applicable\nindications. Added “polyarticular” to juvenile idiopathic arthritis.\nUpdated reference.\n8/2016 Added the indication and criteria for uveitis. Updated background and\nreferences.\n8/2017 Annual review. Reformatted criteria for Crohn’s Disease without\nchanges in clinical intent. Updated reference.\n8/2018 Annual review. Added Olumiant (baricitinib) to the applicable criteria.\nUpdated reference.\n8/2019 Annual review with no changes to coverage criteria. Updated\nbackground and references.\n4/2020 Updated criteria to allow for pediatric Crohn’s disease. Updated\nreauthorization approval duration for all diagnoses.\n5/2021 Updated Crohn’s disease and ulcerative colitis coverage criteria\naccording to FDA label.\n12/2021 Updated initial authorization for UC to 12 months.\n12/2022 Annual review. Renamed program to Adalimumab: Humira®\n(adalimumab) and Amjevita™ (adalimumab-atto) to add Amjevita to the\nprogram. Replaced Humira with adalimumab throughout the program\nto allow coverage for either Humira or Amjevita with no change to\noverall coverage criteria. Added Rinvoq as JAK inhibitor example.\nAdded state mandate footnote. Updated reference.\n4/2023 Added Cyltezo to the program. Updated references.\n6/2023 Added Abrilada (adalimumab-afzb), Adalimumab-adaz (unbranded\nHyrimoz), Adalimumab-fkjp",
    "\nAdded state mandate footnote. Updated reference.\n4/2023 Added Cyltezo to the program. Updated references.\n6/2023 Added Abrilada (adalimumab-afzb), Adalimumab-adaz (unbranded\nHyrimoz), Adalimumab-fkjp (unbranded Hulio), Hyrimoz\n(adalimumab-adaz), Hadlima (adalimumab-bwwd), Hulio\n(adalimumab-fkjp), Idacio (adalimumab-aacf), Yusimry (adalimumab-\naqvh), and Yuflyma (adalimumab-aaty). Added notation some are\nexcluded from coverage for the majority of our benefits. Updated\nreferences. Updated not receiving in combination language to targeted\nimmunomodulator and updated examples.\n6/2024 Annual review. Added Adalimumab-aacf (unbranded Idacio),\n© 2025 UnitedHealthcare Services, Inc.\n9\nAdalimumab-adbm (unbranded Cyltezo), and Simlandi (adalimumab-\nryvk) to the program. Noted Humira, Hadlima, Amjevita high\nconcentration, Adalimumab-adbm (unbranded Cyltezo), and\nAdalimumab-adaz (unbranded Hyrimoz) as covered products. All other\nproducts are noted as excluded. Updated references.\n10/2024 Updated to note Adalimumab-adaz (unbranded Hyrimoz), Amjevita for\nNuvaila, and Humira as covered products. All other products are noted\nas excluded.\n4/2025 Removed notation that only Amjevita (adalimumab-atto) for Nuvaila is\ncovered. All other Amjevita (adalimumab-atto) products are excluded\nfrom coverage for the majority of our benefits. Updated Stelara\nexamples to ustekinumab. Added Entyvio (vedolizumab), Omvoh\n(mirikizumab-mrkz), Tremfya (guselkumab) as examples of not used in\ncombination for UC and CD.\n© 2025 UnitedHealthcare Services, Inc.\n10"
  ]
}